<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        106-68-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ATROVENT 500MCG-2ML UDV (SOLUTION FOR INHALATION)
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IPRATROPIUM BROMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Nebuliser solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        42.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Laboratoire Unither" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Laboratoire Unither
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03BB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ipratropium bromide is a bronchodilator.</p><p>&nbsp;</p><p>ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION is used:</p><p>&nbsp;</p><p>For the prevention and treatment of dyspnoea in</p><p>□&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic obstructive pulmonary disease (COPD)</p><p>□&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mild to moderate bronchial asthma in adults and children, as a supplement to beta2-agonists in&nbsp;an acute asthma attack.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION</p><p>&nbsp;</p><p>□&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to ipratropium bromide, atropine or atropine derivatives (anticholinergic substances with a similar structure) or to any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before using ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION. Care must be taken to ensure that the solution or inhalation mist does not get into the eyes.</p><p>ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION should be used with caution in patients prone to</p><p>narrow-angle glaucoma.</p><p>If this medicine accidentally gets into the eyes during use, mild and reversible eye complications may occur. In particular, patients with increased inner eye pressure (narrow-angle glaucoma) may experience an acute glaucoma attack with the following typical symptoms: eye pain, blurred vision, cloudy vision, coloured halos around light sources or seeing false colours, reddened eyes and corneal swelling.</p><p>If the pupils become dilated and if mild, temporary problems with adjustment of the eyes to different visual ranges (accommodation disorders) should occur, these can be treated with eye drops that constrict the pupils (miotic eye drops). If serious eye complications occur, an eye specialist should also be consulted.</p><p>If possible, a mouthpiece rather than a face mask should be used in such patients during inhalation, so that the medicine does not get into the eyes.</p><p>&nbsp;</p><p>In patients with bladder-emptying problems (e.g. in patients with an enlarged prostate or narrowing of the bladder neck), ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION should be used with caution.</p><p>&nbsp;</p><p>Disturbances in gastrointestinal function and motility are more likely to occur in patients with cystic fibrosis.</p><p>&nbsp;</p><p>If dyspnoea suddenly gets worse during inhalation (paradoxical bronchospasm), treatment must be stopped immediately and replaced by the doctor with a different therapy.</p><p>&nbsp;</p><p>Immediate-type hypersensitivity reactions can occur after use of ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION, e.g. rare cases of skin rash (exanthema), hives (urticaria), shock-like allergic reactions, including massive swelling (angioedema) of the tongue, lips and face and spasm of the bronchial muscles (bronchospasm).</p><p>&nbsp;</p><p>Other medicines and ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines.</p><p>&nbsp;</p><p>Permanent use of ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION with other active substances similar to ipratropium bromide (anticholinergic agents) has not been studied and is therefore not recommended.</p><p>&nbsp;</p><p>Beta-adrenergic agents and xanthine preparations (e.g. theophylline) can increase its effect.</p><p>&nbsp;</p><p>Other anticholinergic agents, such as preparations containing pirenzepine, can increase its effect and side effects.</p><p>&nbsp;</p><p>The risk of an acute glaucoma attack in patients with narrow-angle glaucoma may be increased if ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION and beta-agonists are used together.</p><p>&nbsp;</p><p>Please note that this information can also apply to medicines recently used.</p><p>&nbsp;</p><p>ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION with food and drink</p><p>&nbsp;</p><p>No restrictions apply.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>&nbsp;</p><p><u>Pregnancy and breast-feeding</u></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>There is no experience in humans with regard to use during pregnancy and breast-feeding. Although no harmful effects on the foetus are known to date, ATROVENT 500 &micro;g/2 mL</p><p>SOLUTION FOR INHALATION should not be used during pregnancy, particularly during the first three months of</p><p>pregnancy or while breast-feeding, unless your treating doctor thinks it necessary, after careful consideration of the benefits and risks.</p><p>In so doing, due consideration should be given to the risks of inadequate treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No clinical data on fertility are available for ipratropium bromide. Non-clinical studies with ipratropium bromide showed no adverse effect on fertility.</p><p>&nbsp;</p><p>Driving and using machines</p><p>&nbsp;</p><p>No studies on the ability to drive and use machines have been performed. During treatment with ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION, adverse effects such as dizziness, problems with adjustment of the eyes to different visual ranges (accommodation disorders), temporary pupil dilation (mydriasis) and blurred vision may occur. Caution should therefore be exercised when driving or using machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Please follow the instructions for use, as ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION may otherwise not work properly.</p><p>ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION is intended for inhalation with a nebuliser only.</p><p>&nbsp;</p><p>The dosage must be adapted to each individual case.</p><p>Unless otherwise prescribed, the following dosage recommendations generally apply:</p><p>&nbsp;</p><p>For acute treatment:</p><p>Adults and adolescents over 12 years:</p><p>The inhaled single dose is 0.5 mg ipratropium bromide, corresponding to 1 unit-dose vial. Repeated doses may be administered until the dyspnoea improves. The interval between individual inhalations must be decided by the doctor.</p><p>&nbsp;</p><p>For long-term treatment:</p><p>Adults and adolescents over 12 years:</p><p>1&nbsp; unit-dose vial 3-4 times a day.</p><p>&nbsp;</p><p>Note:</p><p>&nbsp;</p><p>A daily dose of more than 2 mg ipratropium bromide (4 unit-dose vials) should be reviewed regularly by the doctor.</p><p>&nbsp;</p><p>Important note:</p><p>If, despite the prescribed therapy, there is no satisfactory improvement or if your condition gets worse, medical advice is required, so that the treatment can be reviewed and, if necessary, supplemented with other medicines (corticosteroids, beta-sympathomimetics, theophylline).</p><p>In the event of acute or rapidly worsening dyspnoea, medical help must be sought immediately.</p><p>&nbsp;</p><p>How and when to use ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION</p><p>&nbsp;</p><p>This solution is ready for use, i.e. no dilution is required. The solution in unit-dose vials is for inhalation only using suitable inhalation devices and must not be swallowed or injected.</p><p>ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION can be used with standard nebuliser devices; if oxygen is administered, the ideal flow rate is 6&ndash;8 L/min.</p><p>&nbsp;</p><p>If possible, this medicine should be administered while you are sitting or standing.</p><p>&nbsp;</p><p>Instructions for use</p><p>&nbsp;</p><p>1.&nbsp; Prepare your inhalation device (nebuliser) according to the manufacturer&#39;s instructions and as directed by your treating doctor.</p><p>&nbsp;</p><p>2.&nbsp; Separate a unit-dose vial from the strip (see Fig. 1).</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image2.jpeg" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;margin-left:92.5pt;margin-top:12.35pt;width:108.75pt;
  height:108.75pt;z-index:251655680;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="145" height="145" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>Fig. 1</p><p>&nbsp;</p><p>3.&nbsp; Open the vial by twisting off the top (tear-off tab) (see Fig. 2).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image3.jpeg" o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
  margin-left:92.5pt;margin-top:12.35pt;width:108.75pt;height:108.75pt;
  z-index:251656704;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="145" height="145" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>Fig. 2</p><p>&nbsp;</p><p>4.&nbsp; Transfer the contents to the nebuliser chamber by repeated squeezing of the unit-dose vial (see Fig. 3).</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="image4.jpeg" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:109pt;
 height:109pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="145" height="145" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p><p>Fig. 3</p><p>&nbsp;</p><p>5.&nbsp; Reassemble the nebuliser and inhale the solution as directed.</p><p>&nbsp;</p><p>6.&nbsp; After the inhalation, remove any remaining solution from the nebuliser chamber and clean the nebuliser according to the instructions.</p><p>&nbsp;</p><p>Care must be taken to ensure that the solution or inhalation mist does not get into the eyes. The nebulised solution should be inhaled through a mouthpiece. If no mouthpiece is available and a nebuliser mask is used, you must ensure that it is correctly fitted. Patients prone to glaucoma should take particular care to ensure that their eyes are protected during inhalation.</p><p>&nbsp;</p><p>As the solution contains no preservative, the contents of the unit-dose vial must be inhaled immediately after opening; any remaining solution should be discarded.</p><p>&nbsp;</p><p>A fresh unit-dose vial should be used for each dose. If already broached, accidentally opened or damaged, unit-dose vials should be discarded.</p><p>&nbsp;</p><p>ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION is suitable for simultaneous inhalation with mucolytic agents such as ambroxol hydrochloride and bromhexine hydrochloride or fenoterol hydrobromide.</p><p>&nbsp;</p><p>ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION and DSCG (disodium cromoglycate) solutions should not be inhaled at the same time in the same nebuliser.</p><p>&nbsp;</p><p>How long should you use ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION?</p><p>&nbsp;</p><p>The duration of treatment will be decided by your doctor and will depend upon the current state of your illness.</p><p>&nbsp;</p><p>Please talk to your doctor or pharmacist if you have the impression that the effect of ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION is too strong or too weak.</p><p>&nbsp;</p><p>What precautions must be followed?</p><p>&nbsp;</p><p>If you use more ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION than you should</p><p>&nbsp;</p><p>If you have far exceeded the prescribed dose, you should seek medical help immediately. You might be at greater risk of experiencing side effects, such as dry mouth, problems with adjustment of the eyes to different visual ranges and increased heart rate.</p><p>&nbsp;</p><p>If you forget to use ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION</p><p>&nbsp;</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>Inhale the next dose at the specified time. If you constantly use too low doses, there is a risk that your dyspnoea will increase.</p><p>&nbsp;</p><p>If you stop using ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION</p><p>&nbsp;</p><p>Your illness may get worse if you interrupt treatment with ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION or stop it too soon.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The commonest side effects (in 1-10% of patients) occurring with the use of ATROVENT are headache, dizziness, cough, throat irritation, dry mouth, altered taste, disturbances in gastrointestinal motility and nausea.</p><p>&nbsp;</p><p>Certain uncommon side effects may occur (in 0.1-1% of patients). These include: immediate-type allergic reactions, hypersensitivity reactions, blurred vision, temporary pupil dilation, increased inner eye pressure, possibly with eye pain, cloudy vision and seeing rainbow colours (halos), increased blood flow to the conjunctiva, corneal swelling, glaucoma, increased palpitations, supraventricular heart rhythm disorders with increased heart rate, (inhalation-induced) bronchospasm (spasm of the bronchial muscles), spasm of the laryngeal muscles, throat swelling, dry throat, constipation, diarrhoea, abdominal pain, vomiting, inflammation of the mouth lining, swollen mouth, skin rash, itching, massive swelling of the tongue, lips and face, urinary retention.</p><p>&nbsp;</p><p>Certain side effects can occur rarely (in 0.01-0.1% of patients). These include: problems with adjustment of the eyes to differing visual ranges, atrial fibrillation of the heart, hives.</p><p>As with all inhaled medicines, signs of local irritation in the throat region can occur in some patients. <u>Reporting of side effects</u></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects</p><p>not listed in this leaflet.</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the unit-dose vial and carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Storage conditions</p><p>&nbsp;</p><p>Do not store above 30&deg;C. Keep in the original carton.</p><p>&nbsp;</p><p>Shelf life after opening</p><p>&nbsp;</p><p>As the solution contains no preservative, the contents of the unit-dose vial must be inhaled immediately after opening; any remaining solution should be discarded.</p><p>&nbsp;</p><p>If already broached, accidentally opened or damaged, unit-dose vials should be discarded.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater (e.g. down the toilet or washbasin). Ask at your pharmacy how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: ipratropium bromide</p><p>&nbsp;</p><p>2 mL solution (contents of one unit-dose vial) contain:</p><p>522 &micro;g ipratropium bromide 1 H2O (equivalent to 500 &micro;g ipratropium bromide)</p><p>&nbsp;</p><p>The other ingredients are:</p><p>sodium chloride, 3.6% hydrochloric acid (for pH adjustment), purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Clear, colourless nebuliser solution in a colourless, transparent, plastic unit-dose vial. 10 unit-dose vials are packed in a hermetically sealed, white aluminium pouch.

ATROVENT 500 µg/2 mL SOLUTION FOR INHALATION is available in the following pack sizes: Pack with 50 x 2 mL unit-dose vials

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>&nbsp;</p><p>Boehringer Ingelheim Pharma GmbH &amp; Co. KG Binger Str. 173</p><p>55216 Ingelheim am Rhein Germany</p><p>&nbsp;</p><p>&nbsp;</p><p>Manufacturer</p><p>&nbsp;</p><p>Laboratoire Unither Espace Industriel Nord</p><p>151 rue Andr&eacute; Durouchez &ndash; CS 28028 80084 Amiens Cedex 2</p><p>France</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>&nbsp;</p><p>Kingdom of Saudi Arabia (Scientific Office)</p><p>Riyadh.</p><p>Tel: +966-11-5116504</p><p>Fax: +966-11-5116545</p><p>&nbsp;</p><p>This leaflet was last revised in August 2020.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="_x0000_s1027" style='position:absolute;margin-left:92.5pt;margin-top:11.55pt;
  width:371.75pt;height:.45pt;z-index:-251658237;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="1850,231" coordsize="7435,9">
  <v:line id="_x0000_s1028" style='position:absolute' from="1850,235" to="2263,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1029" style='position:absolute' from="2265,235" to="2677,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1030" style='position:absolute' from="2679,235" to="3091,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1031" style='position:absolute' from="3093,235" to="3504,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1032" style='position:absolute' from="3506,235" to="3918,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1033" style='position:absolute' from="3920,235" to="4328,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1034" style='position:absolute' from="4330,235" to="4742,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1035" style='position:absolute' from="4744,235" to="5155,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1036" style='position:absolute' from="5157,235" to="6806,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1037" style='position:absolute' from="6808,235" to="7222,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1038" style='position:absolute' from="7224,235" to="7634,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1039" style='position:absolute' from="7636,235" to="8047,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1040" style='position:absolute' from="8049,235" to="8461,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1041" style='position:absolute' from="8463,235" to="8871,235"
   strokeweight=".14617mm"/>
  <v:line id="_x0000_s1042" style='position:absolute' from="8873,235" to="9285,235"
   strokeweight=".14617mm"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="497" height="1" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>Properties</p><p>ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION is a medicine specifically for the prevention and treatment of dyspnoea in chronic obstructive pulmonary disease (COPD), mild to moderate bronchial asthma and as a supplement to beta2-agonists in an acute asthma attack. Due to the site of action of the active substance in ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION, which is an anticholinergic agent, spasms of the bronchial muscles, triggered by the vagus nerve, are inhibited. This differentiates it from most other antispasmodic inhaled preparations.</p><p>&nbsp;</p><p>ATROVENT 500 &micro;g/2 mL SOLUTION FOR INHALATION dilates the airways. Regular use protects against constriction of the airways and spasms of the bronchial muscles.</p><p>&nbsp;</p><p>Description of the pharmaceutical form</p><p>Clear, colourless solution</p><p>&nbsp;</p><p>&nbsp;</p><p>Other pharmaceutical forms</p><p>&nbsp;</p><p>ATROVENT 250 &micro;g/2 mL SOLUTION FOR INHALATION, nebuliser solution</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&bull;&nbsp; <em>Saudi Arabia:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&bull;&nbsp; <em>Other countries:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='width:489.1pt;
 height:138.5pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokeweight=".48pt">
 <v:textbox style='mso-next-textbox:#_x0000_s1026' inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-left:189.35pt;line-height:13.65pt;
    mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'><span
    lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>This is a
    Medicament<o:p></o:p></span></b></p>
    <p class=MsoBodyText style='margin-top:.3pt'><span lang=EN-US
    style='font-size:11.5pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoBodyText style='margin-top:0cm;margin-right:6.55pt;margin-bottom:
    0cm;margin-left:5.15pt;margin-bottom:.0001pt;text-indent:0cm;mso-list:l0 level1 lfo3;
    tab-stops:14.9pt'><![if !supportLists]><span lang=EN-US style='font-size:
    12.0pt;mso-bidi-language:EN-US'><span style='mso-list:Ignore'>−<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span lang=EN-US>Medicament is a product which affects your
    health and its consumption contrary to an<span style='letter-spacing:-.7pt'>
    </span>instruction is dangerous for<span style='letter-spacing:.1pt'> </span>you.<o:p></o:p></span></p>
    <p class=MsoBodyText style='margin-top:0cm;margin-right:7.55pt;margin-bottom:
    0cm;margin-left:5.15pt;margin-bottom:.0001pt;text-indent:0cm;mso-list:l0 level1 lfo3;
    tab-stops:14.9pt'><![if !supportLists]><span lang=EN-US style='font-size:
    12.0pt;mso-bidi-language:EN-US'><span style='mso-list:Ignore'>−<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span lang=EN-US>Follow strictly the doctor’s prescription,
    the method of use and the instructions of the<span style='letter-spacing:
    -.9pt'> </span>Pharmacist who sold the<span style='letter-spacing:-.1pt'> </span>medicament.<o:p></o:p></span></p>
    <p class=MsoBodyText style='margin-top:.05pt;margin-right:0cm;margin-bottom:
    0cm;margin-left:14.85pt;margin-bottom:.0001pt;text-indent:-9.7pt;
    mso-list:l0 level1 lfo3;tab-stops:14.9pt'><![if !supportLists]><span
    lang=EN-US style='font-size:12.0pt;mso-bidi-language:EN-US'><span
    style='mso-list:Ignore'>−<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span lang=EN-US>The doctor and the pharmacist are the
    experts in medicines, their benefits and<span style='letter-spacing:-.4pt'>
    </span>risks.<o:p></o:p></span></p>
    <p class=MsoBodyText style='margin-left:14.85pt;text-indent:-9.7pt;
    mso-list:l0 level1 lfo3;tab-stops:14.9pt'><![if !supportLists]><span
    lang=EN-US style='font-size:12.0pt;mso-bidi-language:EN-US'><span
    style='mso-list:Ignore'>−<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span lang=EN-US>Do not by yourself interrupt the period of
    treatment prescribed for<span style='letter-spacing:-.15pt'> </span>you.<o:p></o:p></span></p>
    <p class=MsoBodyText style='margin-left:14.85pt;text-indent:-9.7pt;
    mso-list:l0 level1 lfo3;tab-stops:14.9pt'><![if !supportLists]><span
    lang=EN-US style='font-size:12.0pt;mso-bidi-language:EN-US'><span
    style='mso-list:Ignore'>−<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span lang=EN-US>Do not repeat the same prescription without
    consulting your<span style='letter-spacing:-.15pt'> </span>doctor.<o:p></o:p></span></p>
    <p class=MsoBodyText style='margin-left:14.85pt;text-indent:-9.7pt;
    mso-list:l0 level1 lfo3;tab-stops:14.9pt'><![if !supportLists]><span
    lang=EN-US style='font-size:12.0pt;mso-bidi-language:EN-US'><span
    style='mso-list:Ignore'>−<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span lang=EN-US>Keep all medicaments out of reach of<span
    style='letter-spacing:.2pt'> </span>children.<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=EN-US><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="656" height="189" alt="Text Box: This is a Medicament

−	Medicament is a product which affects your health and its consumption contrary to an instruction is dangerous for you.
−	Follow strictly the doctor’s prescription, the method of use and the instructions of the Pharmacist who sold the medicament.
−	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
−	Do not by yourself interrupt the period of treatment prescribed for you.
−	Do not repeat the same prescription without consulting your doctor.
−	Keep all medicaments out of reach of children.

" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:489.1pt;height:138.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in August 2020.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إبراتروبيوم بروميد هو مُوَسِّع شُعَبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق لعلاج الآتي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">للوقاية والعلاج من ضيق التَّنفس في</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة مرض الانسداد الرئوي المزمن COPD)).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو الشُّعَبي الخفيف إلى المعتدل في البالغين والأطفال، كمكمل لناهضات بيتا2في حالات نوبة الربو الحادة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه إبراتروبيوم بروميد أو مشتقات الأتروبين (مواد مضادة للفعل الكوليني ذات تكوين متماثل) أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل استخدام عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب توخي الحذر للتأكَّد من عدم دخول &nbsp;المحلول أو رذاذ الاستنشاق إلى العينين .</p><p dir="RTL">يجب استخدام عقار أتروفنت<sup> </sup>&nbsp;500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق &nbsp;بحذر في المرضى المعرضين للإصابة بزرق ضيِّق الزاوية.</p><p dir="RTL">إذا دخل هذا الدَّواء في عينيك بطريق الخطأ أثناء الاستخدام، فقد تحدث مضاعفات بسيطة وقابلة للارتداد بالعين. على وجه الخصوص، قد يعاني المرضى المصابون بارتفاع ضغط العين الدَّاخلي (زرق ضيِّق الزاوية) من نوبة زَرَق حادة مصحوبة بالأعراض النمطية التَّالية: ألم بالعين، عدم وضوح الرؤية، رؤية ضبابية، هالات ملونة حول مصادر الضوء أو رؤية ألوان زائفة، احمرار العينين وتورم القرنية.</p><p dir="RTL">إذا حدث اتساع &nbsp;في الحدقتين، &nbsp;و إذا حدثت مشاكل طفيفة و مؤقتة في ضبط العينين على المسافات البصرية المختلفة (اضطرابات التكيف)، ومن الممكن علاج هذه المشاكل باستخدام قطرات العين التي تضيق الحدقتين (قطرات العين القابضة للحدقة).&nbsp;&nbsp; إذا حدثت مضاعفات خطيرة بالعين، يجب أيضًا استشارة أخصائي عيون.</p><p dir="RTL">إذا أمكن، يجب استخدام قطعة الفم بدلًا من قناع الوجه في هؤلاء المرضى أثناء الاستنشاق، حتى لا يدخل&nbsp; الدَّواء داخل العينين.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام عقار أتروفنت<sup> </sup>500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق مع &nbsp;بحذر في المرضى الذين يعانون من مشاكل إفراغ المثانة (على سبيل المثال: في المرضى الذين يعانون من تضخم البروستاتا أو ضيق بعنق المثانة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المرجح حدوث اضطرابات في وظيفة و حركية الجهاز الهضمي &nbsp;في المرضى الذين يعانون من التليُّف الكيسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدث تفاقم بشكل مفاجئ بضيق التَّنفس أثناء الاستنشاق (التَّشنج القصبي التناقضي)، يجب إيقاف العلاج فورًا ويتم استبداله بعلاج مختلف من قبل الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمكِن أن تحدث تفاعلات فرط حساسية من النَّوع الفوري بعد استخدام عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق، مثل حدوث حالات نادرة من الطفح الجلدي (الطَّفَح الظاهِر) &nbsp;الشرى (أرتكاريا)، وتفاعلات حساسية شبيهة بالصدمة، بما في ذلك تورم جسيم (وذمة وعائية) باللسان والشفتين والوجه وتقلصات عضلات الشعب الهوائية (التشنج القصبي).</p><p dir="RTL">الأدوية الأخرى وعقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق</p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول/ تستخدم أو تناولت/ استخدمت مؤخرًا أو قد تتناول/ تستخدم أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم تتم دراسة الاستخدام الدَّائم لعقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق مع المواد الأخرى المماثلة لإبراتروبيوم بروميد (مضادات الفعل الكوليني)&nbsp; ولذا لا يُوصى باستخدامها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن أن تزيد أدوية بيتا الأدرينية ومستحضرات الزانثين (مثل ثيوفيلين) من تأثيره.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مضادات الفعل الكوليني الأخرى، مثل المستحضرات التي تحتوي على بايرنزيبين، يمكن أن تزيد من &nbsp;تَّأثيره و&nbsp; آثاره الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزداد خطر الإصابة بنوبة زرق حادة في المرضى الذين يعانون من زرق ضيِّق الزاوية إذا تم استخدام عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق بالتَّزامن مع ناهضات بيتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى ملاحظة أنَّ هذه المعلومات يمكن أن تنطبق أيضًا على الأدوية التي تم استخدامها مؤخرًا.</p><p dir="RTL">استخدام عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق مع الأطعمة والمشروبات</p><p dir="RTL">لا تنطبق أيَّة قيود.</p><p dir="RTL">الحمل والرَّضاعة الطبيعية والخصوبة</p><p dir="RTL"><u>الحمل والرضاعة الطبيعية</u></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبك أو الصيدلي الخاص بك قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا توجد هناك خبرة بالنِّسبة للبشر فيما يتعلق بالاستخدام أثناء الحمل والرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على الرَّغم من عدم وجود تأثيرات ضارة معروفة على الأجنة حتى اليوم، فيجب عدم استخدام عقار أتروفنت<sup> </sup>500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق أثناء الحمل، وخاصةً أثناء الثلاثة أشهر الأولى من الحمل، أو أثناء الرضاعة الطبيعيَّة، ما لم ير طبيبكِ المعالج ذلك ضروريًّا، بعد دراسة متأنية للمخاطر والفوائد.</p><p dir="RTL">عند القيام بذلك، ينبغي إيلاء الاعتبار الكافي لمخاطر عدم كفاية العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">لا تتوافر بيانات سريرية حول الخصوبة لإبراتروبيوم بروميد. لم تُظهِر الدراسات غير السريرية الخاصة بإبراتروبيوم بروميد أيَّة آثار جانبية على الخصوبة.</p><p>القيادة واستخدام الآلات</p><p dir="RTL">لم يتم إجراء أيَّة دراسات بشأن القدرة على ممارسة القيادة واستخدام الآلات. أثناء العلاج بعقار أتروفنت<sup> </sup>500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق، قد تحدث آثار جانبية مثل: الدوخة، ومشاكل في ضبط العينين على المسافات البصرية المختلفة (مشاكل التَّكَيُّف) وتوسُّع مؤقت بحدقة العين (توسُّع حدقة العين) وعدم وضوح الرؤية. لذا يجب توخي الحذر عند ممارسة القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع الطبيب أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى الالتزام بتعليمات الاستخدام؛ إذ قد لا يعمل عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق بشكل صحيح خلاف ذلك.</p><p dir="RTL">لا يستخدم عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق إِلَّا للاستنشاق عن طريق جهاز رذَّاذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب مواءمة الجرعة لكل حالة فردية على حدة.</p><p dir="RTL">ما لم يوصف خلاف ذلك، يتم تطبيق توصيات الجرعة التَّالية بشكل عام:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>لعلاج الحالات الحادة:</strong></p><p dir="RTL"><em>البالغون والمراهقون أكبر من 12 سنة:</em></p><p dir="RTL">تبلغ جرعة واحدة مستنشقة 0.5 مجم من إبراتروبيوم بروميد، ما يُعادل زجاجة واحدة لكل جرعة مفردة . يمكن تناول &nbsp;جرعات&nbsp; متكررة حتى يتحسن ضيق التَّنفس، ويجب تحديد الفاصل الزمني بين مرات الاستنشاق الفردية من قبل الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بالنسبة للعلاج طويل الأمد:</strong></p><p dir="RTL"><em>البالغون والمراهقون أكبر من 12 سنة:</em></p><p dir="RTL">زجاجة واحدة لكل جرعة مفردة 3-4 مرات في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ملاحظة:</strong></p><p dir="RTL">يجب مراجعة الجرعة اليومية بانتظام من قبل الطبيب، إذا زادت عن 2 مجم إبراتروبيوم بروميد (زجاجات للجرعات بحجم 4 وحدات) بانتظام من قبل الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ملحوظة هامَّة:</strong></p><p dir="RTL">إذا لم يوجد تحسن مُرضٍ على الرَّغم من العلاج الموصوف، أو إذا تفاقمت حالتك، فلا بد من طلب المشورة الطبية، بحيث يمكن مراجعة العلاج، وإذا لزم الأمر، يتم إضافة عقاقير أخرى &nbsp;كمكملات (الكورتيكوستيرويدات، محاكيات الودي السمبثاوي-بيتا، الثيوفيلين).&nbsp;</p><p dir="RTL">في حالة حدوث ضيق حاد في التَّنفس أو تفاقمه بشكل سريع، فيجب طلب المساعدة الطبية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف&nbsp; &nbsp;</strong><strong>ومتى يتم</strong><strong> </strong><strong>استخدام عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد هذا المحلول جاهزًا للاستخدام، أي لا يتطلب أي تخفيف. يوجد هذا المحلول في زجاجات الجرعة المفردة &nbsp;وهو مُعد للاستنشاق فقط عن طريق استخدام أجهزة الاستنشاق المناسبة ويجب عدم ابتلاعه أو حقنه.</p><p dir="RTL">يمكن استخدام عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق مع أجهزة الرذاذ القياسية، إذا تم إعطاء الأكسجين، يكون معدل التَّدفق المثالي هو 6-8 لترات/ الدقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن أمكن، يجب إعطاء هذا الدَّواء أثناء الجلوس أو الوقوف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات الاستعمال</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">1. قم بإعداد جهاز الاستنشاق الخاص بك (جهاز رذَّاذ) تبعًا لتوجيهات الشركة المصنعة وبحسب توجيهات طبيبك المعالج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">2. افصل زجاجة واحدة لجرعة مفردة &nbsp;من الشريط (انظر الشكل 1).</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Bild_x0020_2" o:spid="_x0000_i1025" type="#_x0000_t75"
   style='width:116pt;height:116pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="155" height="155" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td></tr></tbody></table><p dir="RTL">شكل 1</p><p dir="RTL">3. افتح الزجاجة عن طريق لف الجزء العلوي منها (غطاء قابل للخلع) (انظر الشكل 2).</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Bild_x0020_3" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:116pt;
   height:116pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="155" height="155" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td></tr></tbody></table><p dir="RTL">شكل 2</p><p dir="RTL">4. قم بنقل المحتويات إلى غرفة الجهاز الرذَّاذ عن طريق الضغط المتكرر على زجاجة &nbsp;الجرعة المفردة (انظر الشكل 3).</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Bild_x0020_4" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:116pt;
   height:116pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="155" height="155" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td></tr></tbody></table><p dir="RTL">شكل 3</p><p dir="RTL">5. أعد تجميع الجهاز الرذَّاذ واستنشق المحلول بحسب التَّوجيهات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">6. بعد الاستنشاق، قم بإزالة أي محلول متبق من غرفة الجهاز الرذَّاذ وقم بتنظيف الجهاز الرذَّاذ بحسب التعليمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب توخي الحذر للتأكَّد من عدم دخول المحلول أو رذاذ الاستنشاق إلى العينين . يجب استنشاق المحلول الرذاذي من خلال قطعة الفم. إذا لم تكن قطعة الفم متاحة وتم استخدام قناع الجهاز الرذَّاذ، فيجب عليك التَّأكد من أنه تم تركيبه بشكل صحيح. يجب على المرضى المعرضين للإصابة بالزَّرَق اتخاذ حذر خاص؛ للتَّأكد من حماية أعينهم أثناء الاستنشاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بما أن المحلول لا يحتوي على مواد حافظة، يجب استنشاق محتويات زجاجة الجرعة المفردة بعد الفتح مباشرة، ويجب التَّخلص من أي محلول متبقٍّ.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام زجاجة جرعة مفردة&nbsp; جديدة لكل جرعة. يجب التَّخلص من زجاجة الجرعة المفردة إذا كانت مثقوبة بالفعل، أو تم فتحها بطريق الخطأ أو كانت تالفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يكون عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق مناسبًا للاستنشاق بالتَّزامن مع الأدوية مزيلة البلغم مثل &nbsp;هيدروكلوريد أمبروكسول وهيدروكلوريد البرومهيكسين أو هيدروبروميد فينوتيرول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم استنشاق عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق ومحاليل كروموجليكات ثنائي الصوديوم في نفس الوقت في نفس الجهاز الرذَّاذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كم المدة التي يجب عليك استخدام عقار أتروفنت<sup> </sup>500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق خلالها؟</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك مدة العلاج وستعتمد على حالتك المرضية الحالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى التَّحدث إلى الطبيب أو الصيدلي الخاص بك إذا كان لديك انطباع بأنَّ تأثير عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق قويٌّ جدًّا أو ضعيفٌ جدًّا.</p><p>ما هي الاحتياطات الواجب اتباعها؟</p><p>إذا استخدمت كمية أكثر مما يجب من عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق</p><p dir="RTL">إذا تجاوزت الجرعة الموصوفة لك بشكل كبير، فيجب عليك طلب المساعدة الطبية على الفور. قد تكون معرضًا لخطر أكبر من التَّعرض للآثار الجانبية، مثل: جفاف الفَم، ومشاكل في ضبط العينين على المسافات البصرية المختلفة وزيادة معدل ضربات القلب.</p><p>إذا أغفلت استخدام عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">استنشق الجرعة التَّالية في الموعد المحدد. إذا كنت تستخدم جرعات منخفضة بشكل مستمر، فسيزداد خطر الإصابة بضيق التَّنفس لديك.</p><p>إذا توقفت عن استخدام عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق</p><p dir="RTL">قد يتفاقم مرضك إذا قطعت العلاج بعقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق أو قمت بإيقافه بشكل مبكر جدًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، استشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الأكثر شيوعًا (في 1-10٪ من المرضى) التي تحدث مع استخدام عقار أتروفنت هي الصُّداع، والدوخة، والسعال، وتهييج بالحلق، وجفاف الفم، تغير بحاسة التَّذوق، واضطرابات في حركة الجهاز الهضمي والغثيان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث بعض الآثار الجانبية غير الشائعة (في 0.1- 1% من المرضى). وتشمل: تفاعلات حساسية من النوع الفوري، تفاعلات فرط الحساسية، عدم وضوح بالرؤية، توسُّعًا مؤقتًا بحدقة العين، ارتفاع ضغط العين الدَّاخلي، قد يصاحبه ألم في العين، رؤية ضبابية أو طيفية (هالات)، زيادة تدفق الدَّم إلى الملتحمة، تورم القرنية، مياهًا زرقاء، خفقانًا متزايدًا، اضطرابات النظم القلبي فوق البطيني مع ارتفاع معدل ضربات القلب، تشنجات قصبية (متعلقة بالاستنشاق) (تقلصات في عضلات الشُّعَب الهوائية)، تقلصات في عضلات الحنجرة، تورم الحلق، جفاف الحلق، الإمساك، الإسهال، ألمًا بالبطن، القيء، التهاب بطانة الفم، تورم الفم، الطفح الجلدي، الحكة، تورمًا جسيما باللسان والشفتين والوجه، احتباس البول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض الآثار الجانبية قد تحدث نادرًا (0.01-0.1٪ من المرضى). يشمل هذا: مشاكل في ضبط العينين على المسافات البصرية المختلفة، الرجفان الأذيني للقلب، شرى (أرتكاريا).</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال مع جميع الأدوية التي يتم استخدامها عن طريق الاستنشاق، فيُمكِن أن تظهر علامات التهيُّج الموضعي في منطقة الحَلْق لدى بعض المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الإبلاغ عن الآثار الجانبية</u></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى الطبيب أو الصيدلي الخاص بك.&nbsp; ويشمل&nbsp; ذلك: أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تَستخدِم هذا الدَّواء بعد انتهاء تاريخ الصَّلاحية المدون على زجاجة الجرعة المفردة وعلى العبوة الكرتونية.&nbsp; يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ظروف التَّخزين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يتم التخزين فوق درجة حرارة 30 درجة مئوية. يخزن داخل العبوة الكرتونية الأصلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عمر التَّخزين بعد الفتح</strong></p><p dir="RTL">بما أن المحلول لا يحتوي على مواد حافظة، يجب استنشاق محتويات زجاجة الجرعة المفردة بعد الفتح مباشرة، ويجب التَّخلص من أي محلول متبقٍّ.&nbsp;</p><p dir="RTL">يجب التَّخلص من زجاجة الجرعة المفردة إذا كانت مثقوبة بالفعل، أو تم فتحها بطريق الخطأ أو كانت تالفة.</p><p dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحي (مثل المرحاض أو حوض الغسيل). اسأل في الصيدلية عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي: إبراتروبيوم بروميد</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي 2 مللي لتر من المحلول (محتويات زجاجة واحدة&nbsp; للجرعة المفردة ) على الآتي:</p><p dir="RTL">522 ميكروجرام إبراتروبيوم بروميد أحادي الهيدرات (ما يُعادل 500 ميكروجرام إبراتروبيوم بروميد)</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">كلوريد الصوديوم، حمض الهيدروكلوريك بنسبة 3.6٪ (لضبط درجة الحموضة)، ماء مُنقى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محلول للاستنشاق عن طريق جهاز رذَّاذ صافٍ، عديم اللون في زجاجة بلاستيكية عديمة اللون وشفافة لجرعة مفردة . تتم تعبئة 10 زجاجات لجرعة مفردة في جراب من الألومنيوم مغلق بإحكام، ذي لون أبيض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر عقار أتروفنت 500 ميكوجرام/ 2 مللي لتر محلول للاستنشاق في عبوات بالأحجام التَّالية:</p><p dir="RTL">عبوة أصلية بها 50 &times; 2 مللي لتر من زجاجات الجرعة المفردة .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التَّسويق</p><p dir="RTL">شركة بوهرينجر إنجلهايم انترناشونال المحدودة</p><p dir="RTL">173 شارع بينجر&nbsp;</p><p dir="RTL">55216 D- إنجلهايم &nbsp;أم راين</p><p dir="RTL">ألمانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التَّصنيع</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">مختبر يونيثير</p><p dir="RTL">&nbsp;المنطقة الصناعية الشمالية</p><p dir="RTL">151 شارع أندريه دوغوشيه &ndash; سي اس 28028</p><p dir="RTL">80084 أميان سيديكس 2</p><p dir="RTL">فرنسا</p><p dir="RTL">للحصول على أي معلومات بخصوص ھذا الدواء یرجى التواصل مع الممثل المحلي (المكتب العلمي)</p><p dir="RTL">هاتف: +966115116504</p><p dir="RTL">فاكس: +966115116545</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>آخر مراجعة لهذه النَّشرة كانت في أغسطس </em><em>2020</em><em>.</em></p><p dir="RTL">________________________________________________________________________</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصائص</strong></p><p dir="RTL">عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق عبارة عن دواء مُعد خصيصًا للوقاية من وعلاج ضيق التَّنفس في حالة مرض الانسداد الرئوي المزمن، ومرض الربو الشُّعَبي البسيط إلى المعتدل وكمكمل لناهضات بيتا 2<sub> </sub>في حالة نوبة الربو الحادة. نظرا لموضع عمل المادة الفعالة في عقار أتروفنت 500 ميكروجرام / 2 مللي لتر محلول للاستنشاق، وهو أحد مضادات الفعل الكوليني، يتم تثبيط تقلصات عضلات الشُّعَب الهوائية التي يثيرها العصب المُبْهَم. وهذا يجعله مختلفًا عن معظم المستحضرات المستنشقة الأخرى المضادة للتقلصات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يقوم عقار أتروفنت 500 ميكروجرام/ 2 مللي لتر محلول للاستنشاق بتوسيع المسالك الهوائية. يحمي الاستخدام المنتظم من تضيُّق المسالك الهوائية وتقلصات عضلات الشُّعَب الهوائية.&nbsp;</p><p dir="RTL"><strong>وصف الشَّكل الصيدلاني</strong></p><p dir="RTL">محلول صافٍ وعديم اللون.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p>الأشكال الصيدلانية الأخرى</p><p dir="RTL">عقار أتروفنت 250 ميكروجرام/ 2 مللي لتر محلول للاستنشاق، محلول للاستنشاق عن طريق جهاز رذَّاذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الاثار الجانبية:</strong></p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong><em>السعودية:</em></strong></p><p dir="RTL"><strong><em>-&nbsp;&nbsp; </em></strong>المركز الوطني للرصد الدوائي</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>فاكس: +966-11-205-7662</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>مركز الاتصال الموحد بالهيئة العامة للغذاء و الدواء: 19999</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>موقع الويب: www.sfda.gov.sa/npc</p><p dir="RTL"><strong><em>-&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>الدول الأخرى:</p><p dir="RTL">يرجى الاتصال بالهيئة المختصة.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:652px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>هذا منتج دوائي</strong></p><p dir="RTL">&minus; الدَّواء منتج يُؤثر على صحتك وتناوله على نحو مخالف للتعليمات يعرضك للخطر.</p><p dir="RTL">&minus; اتبع وصفة الطبيب بشكل صارم وطريقة الاستعمال وتعليمات الصيدلي الذي باعك الدَّواء.</p><p dir="RTL">&minus; الطبيب والصيدلي هما خبيران في الأدوية وفوائدها ومخاطرها.</p><p dir="RTL">&minus; لا تقطع فترة العلاج الموصوفة لك من تلقاء نفسك.</p><p dir="RTL">&minus; لا تكرر الوصفة الطبية دون استشارة طبيبك.</p><p dir="RTL">&minus; احفظ جميع الأدوية بعيدًا عن متناول الأطفال.</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجلس وزراء الصحة العرب</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النَّشرة كانت في أغسطس 2020.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Atrovent® UDVs 500 µg/2 ml Nebuliser solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: Ipratropium bromide

Each unit-dose vial holding 2 ml of solution contains:
522 µg ipratropium bromide monohydrate (equivalent to 500 µg ipratropium bromide) For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nebuliser solution 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the prevention and treatment of dyspnoea in:</p><p>□&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic obstructive pulmonary disease (COPD)</p><p>□&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mild to moderate adult and childhood asthma, as an adjunct to 2-agonists during acute asthma&nbsp;attacks.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For inhalation with a nebuliser. <u>Posology</u></p><p>The dosage should be adapted to the individual requirements of the patient.</p><p>&nbsp;</p><p>The following dosages are recommended:</p><p>&nbsp;</p><p>For acute treatment</p><p>Adults and adolescents &gt; 12 years of age:</p><p>The single inhaled dose is 0.5 mg ipratropium bromide, equivalent to 1 vial. Repeated doses can be administered until the dyspnoea has improved. The time interval between the doses must be determined by the physician.</p><p>&nbsp;</p><p>For maintenance treatment</p><p>Adults and adolescents &gt; 12 years of age:</p><p>1&nbsp; vial 3 - 4 times daily.</p><p>&nbsp;</p><p>Note</p><p>Daily doses of more than 2 mg ipratropium bromide (4 vials) must be regularly reviewed by the physician.</p><p>&nbsp;</p><p>&nbsp;</p><p>Important note</p><p>The patient should be medically monitored during treatment.</p><p>If the patient&#39;s condition fails to show a satisfactory improvement or deteriorates despite treatment, medical advice must be sought so that modifications to the treatment plan, including the addition of corticosteroids, 2-agonists or theophylline if necessary, can be made. In the event of acute or rapidly worsening dyspnoea, the patient must be instructed to get medical help immediately.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>The solution is ready to use and does not need to be diluted. It is intended only for inhalation with suitable inhalation devices and must not be taken orally or administered parenterally.</p><p>&nbsp;</p><p>The solution should ideally be administered with the patient in a sitting or standing position. For detailed instructions on use, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Atrovent UDVs 500 µg/2 ml is contraindicated in patients with hypersensitivity to the active substance, to atropine or atropine derivatives (such as ipratropium bromide) or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u></p><p>Immediate hypersensitivity reactions may occur following the use of Atrovent UDVs 500 &micro;g/2 ml, such as rare cases of rash, urticaria, angioedema, oropharyngeal oedema, bronchospasm and anaphylaxis.</p><p>&nbsp;</p><p><u>Paradoxical bronchospasm</u></p><p>As with other inhaled medications, Atrovent UDVs 500 &micro;g/2 ml may cause paradoxical bronchospasm, which may be life-threatening. If paradoxical bronchospasm occurs, Atrovent UDVs 500 &micro;g/2 ml must be discontinued immediately and replaced with an alternative therapy.</p><p>&nbsp;</p><p><u>Special populations:</u></p><p>&nbsp;</p><p><u>Ocular complications</u></p><p>Care must be taken not to allow the solution or mist to enter into the eyes.</p><p>Atrovent UDVs 500 &micro;g/2 ml should be used with caution in patients with a predisposition for narrow- angle glaucoma.</p><p>If the product accidentally comes into contact with the eyes during use, mild, reversible ocular complications may occur. There is a risk of an acute glaucoma attack, particularly in patients with narrow-angle glaucoma; the characteristic symptoms are eye pain, blurred vision, visual halos or coloured images, red eyes and corneal oedema.</p><p>If mydriasis and mild accommodation disorders occur, treatment with miotic drops may be given. In the event of severe ocular complications, an ophthalmologist should also be consulted.</p><p>In these patients, a mouthpiece rather than a face mask should ideally be used for inhalation in order to prevent the product from getting into the eyes.</p><p>&nbsp;</p><p><u>Effect on the kidneys and urinary tract</u></p><p>In patients with micturition disorders (such as in prostatic hypertrophy or bladder neck obstruction), the benefit of treatment with ipratropium bromide must be carefully weighed against the potential risk of aggravating urinary retention.</p><p>&nbsp;</p><p><u>Gastrointestinal motility disorders</u></p><p>&nbsp;</p><p>Patients with cystic fibrosis are more likely to develop gastrointestinal motility disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Chronic use of inhaled Atrovent together with other anticholinergic drugs has not been studied and is therefore not recommended.</p><p>&nbsp;</p><p>-adrenergic agents and xanthine derivatives (such as theophylline) may enhance the therapeutic effect.</p><p>&nbsp;</p><p>Other anticholinergic medications, such as those containing pirenzepine, may increase both the therapeutic and undesirable effects.</p><p>&nbsp;</p><p>The risk of acute glaucoma in patients with narrow-angle glaucoma may be increased when Atrovent UDVs 500 &micro;g/2 ml and -mimetics are administered simultaneously.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy and breast-feeding</u></p><p>There are no data from use in pregnant or breast-feeding women.</p><p>Although no teratogenic effects have been identified to date, Atrovent UDVs 500 &micro;g/2 ml should not be used during pregnancy (especially the first trimester) or while breast-feeding unless considered necessary by the treating physician after careful benefit/risk assessment.</p><p>The risks of inadequate treatment should be given due weight in this assessment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Clinical data on fertility are not available for ipratropium bromide. Non-clinical studies performed with ipratropium bromide showed no adverse effect on fertility (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, patients should be advised that undesirable effects such as dizziness, accommodation disorders, mydriasis and blurred vision may occur during treatment with Atrovent UDVs 500 &micro;g/2 ml. Caution is therefore required when driving or using machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Like all medicines, Atrovent UDVs 500 &micro;g/2 ml can cause side effects.</p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of the safety profile</p><p>Many of the undesirable effects listed can be attributed to the anticholinergic properties of Atrovent.</p><p>&nbsp;</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated summary of undesirable effects</p><p>The undesirable effects listed were identified from clinical trial data and postmarketing surveillance. Their frequency is defined using the following convention:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>( 1/10)</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>( 1/100 - &lt; 1/10)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>( 1/1000 - &lt; 1/100)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>( 1/10,000 - &lt; 1/1000)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>(&lt; 1/10,000)</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>(Frequency cannot be estimated from the available data)</p></td></tr></tbody></table><p>&nbsp;</p><p>Immune system disorders</p><p>&nbsp;</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reactions, hypersensitivity</p><p>&nbsp;</p><p>Nervous system disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, dizziness</p><p>&nbsp;</p><p>Eye disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision, mydriasis, increased intraocular pressure (sometimes with eye pain), foggy vision, halo or rainbow vision, conjunctival hyperaemia and corneal oedema, glaucoma</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accommodation disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>Cardiac disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations, (supraventricular) tachycardia</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrial fibrillation</p><p>&nbsp;</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough, throat irritation</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Paradoxical) bronchospasm, laryngospasm, pharyngeal oedema, dry throat</p><p>&nbsp;</p><p>Gastrointestinal disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth, taste disturbance, gastrointestinal motility disorders, nausea</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, diarrhoea, abdominal pain, vomiting, stomatitis, oral oedema</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, pruritus, angioedema</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urticaria</p><p>&nbsp;</p><p>Renal and urinary disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary retention</p><p>&nbsp;</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common undesirable effects</p><p>As with any other inhaled medication, Atrovent may also be associated with local irritation in the throat. The most common undesirable effects reported in clinical trials were headache, throat irritation, cough, dry mouth, gastrointestinal motility disorders (including constipation, diarrhoea and vomiting), nausea and dizziness.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reaction after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific signs of overdose have been encountered to date.</p><p>&nbsp;</p><p>However, in view of the wide therapeutic window and the fact that the product is administered topically, no serious anticholinergic symptoms are to be expected. Mild systemic anticholinergic side effects such as dry mouth, accommodation disorders and increased heart rate may occur.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other drugs for obstructive airway diseases, inhalants / Anticholinergics ATC code: R03BB01</p><p>&nbsp;</p><p>Ipratropium bromide is a quaternary ammonium compound with anticholinergic (parasympatholytic) properties. In non-clinical studies, it inhibits vagally-mediated reflexes by antagonising the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increase in intracellular concentration of Ca<sup>++</sup> which is caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. Ca<sup>++</sup> release is mediated by the second messenger system consisting of IP3 (inositol triphosphate) and DAG (diacylglycerol).</p><p>&nbsp;</p><p>The bronchodilation following inhalation of Atrovent (ipratropium) is primarily local and specific to the lung and is not systemic in nature.</p><p>&nbsp;</p><p>Non-clinical and clinical evidence suggests that Atrovent (ipratropium) has no adverse effect on airway mucus secretion, mucociliary clearance or gas exchange.</p><p>&nbsp;</p><p><u>Clinical trials</u></p><p>In controlled 85-day to 90-day studies in patients with bronchospasm associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema), significant improvements in lung function occurred within 15 min. These improvements reached a peak in 1 - 2 hours and persisted for 4 - 6 hours.</p><p>&nbsp;</p><p>The bronchodilator effect of Atrovent in the treatment of acute bronchospasm associated with asthma has been demonstrated in studies in adults. In most of these studies, Atrovent was administered in combination with an inhaled 2-agonist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The therapeutic effect of Atrovent is produced by a local action in the airways. Time courses of bronchodilation and systemic pharmacokinetics do not run in parallel.</p><p>&nbsp;</p><p>Following inhalation, 10 - 30% of a dose is generally deposited in the lungs, depending on the formulation and inhalation technique. The majority of the dose is swallowed and passes through the gastrointestinal tract.</p><p>&nbsp;</p><p>The portion of the dose deposited in the lungs reaches the circulation rapidly (within minutes).</p><p>&nbsp;</p><p>Cumulative renal excretion (0 - 24 hours) of parent compound is below 1 % of an oral dose and approx. 3 &ndash; 13 % of an inhaled dose. On the basis of these data, the total systemic bioavailability of oral and inhaled doses of ipratropium bromide is estimated at 2% and 7 - 28% respectively.</p><p>Taking this into account, swallowed portions of ipratropium bromide doses do not contribute significantly to systemic exposure.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Kinetic parameters describing the disposition of ipratropium were calculated from plasma concentrations after intravenous administration. A rapid biphasic decline in plasma concentrations was observed. The apparent volume of distribution at steady state (Vdss) is approx. 176 l (equivalent to</p><p>2.4 l/kg). The drug is minimally (less than 20%) bound to plasma proteins. Non-clinical data indicate that the quaternary ammonium compound ipratropium does not cross the placenta or the blood-brain barrier.</p><p>&nbsp;</p><p>The known metabolites show little or no affinity to the muscarinic receptor and must be regarded as ineffective.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>After intravenous administration, approx. 60% of the dose is metabolised, probably to a large extent by oxidation in the liver.</p><p>&nbsp;</p><p>The known metabolites are formed by hydrolysis, dehydration or elimination of the hydroxymethyl group in the tropic acid moiety.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The terminal elimination half-life is approx. 1.6 hours.</p><p>&nbsp;</p><p>Ipratropium has a total clearance of 2.3 l/min and a renal clearance of 0.9 l/min.</p><p>&nbsp;</p><p>After inhalation of ipratropium bromide with HFA 134a as the propellant, cumulative renal excretion over 24 hours was approx. 12%.</p><p>In an excretion balance study, cumulative renal excretion (6 days) of drug-related radioactivity (including parent compound and all metabolites) was 9.3 % after oral administration and 3.2 % after inhalation. Total radioactivity excreted via the faeces was 88.5 % after oral administration and 69.4 % after inhalation. Drug-related radioactivity after intravenous administration is excreted mainly via the kidneys. The elimination half-life of drug-related radioactivity (parent compound and metabolites) is</p><p>3.6 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Local and systemic tolerability of ipratropium bromide has been comprehensively investigated in several animal species using various administration routes.</p><p>&nbsp;</p><p><u>Single-dose toxicity</u></p><p>Acute inhalational, oral and intravenous toxicity has been assessed in several rodent and non-rodent species.</p><p>When administered by inhalation, the minimum lethal dose in male guinea pigs was 199 mg/kg. In rats, no mortality was observed up to the highest technically feasible doses (0.05 mg/kg after 4 hours of administration or 160 puffs of ipratropium bromide at a dose of 0.02 mg/puff).</p><p>The oral LD50 values for mice, rats and rabbits were 1585, 1925 and 1920 mg/kg respectively. The intravenous LD50 values for mice, rats and dogs were 13.6, 15.8 and approx. 18.2 mg/kg respectively. Clinical symptoms included mydriasis, dry oral mucosa, dyspnoea, tremor, spasms and/or tachycardia.</p><p>&nbsp;</p><p><u>Repeated-dose toxicity</u></p><p>Repeated-dose toxicity studies have been performed in rats, rabbits, dogs and rhesus monkeys.</p><p>In inhalation studies up to 6 months in rats, dogs and rhesus monkeys, the no observed adverse effect levels (NOAELs) were 0.38 mg/kg/day, 0.18 mg/kg/day and 0.8 mg/kg/day respectively. Dryness of the oral mucosa and tachycardia were noted in dogs. No histopathological lesions related to ipratropium bromide were observed in the bronchopulmonary system or in any other organs. In rats, the NOAEL after 18 months of oral administration was 0.5 mg/kg/day.</p><p>&nbsp;</p><p>Repeated-dose inhalation toxicity studies in rats for up to 6 months and in dogs for up to 3 months with other formulations (intranasal formulation, alternative propellant HFA 134a and lactose powder formulations) revealed no additional information on the general toxicity profile of ipratropium bromide.</p><p>Intranasal administration for up to 6 months revealed a no effect level (NOEL) of &gt; 0.20 mg/kg/day in dogs and confirmed the results of earlier studies with intranasal administration for up to 13 weeks.</p><p>Repeated-dose toxicity studies of ipratropium bromide have shown the toxicological profiles of the HFA formulation and the conventional CFC formulation to be similar.</p><p>&nbsp;</p><p><u>Local tolerability</u></p><p>An aqueous solution of ipratropium bromide (0.05 mg/kg) was locally well tolerated when administered to rats by inhalation (single administration over 4 hours). In the repeated-dose toxicity study, ipratropium bromide was locally well tolerated.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>Neither active anaphylaxis nor passive cutaneous anaphylactic reactions occurred in guinea pigs.</p><p>&nbsp;</p><p><u>Genotoxicity and carcinogenicity</u></p><p>There was no evidence of genotoxicity in vitro (Ames test) or in vivo (micronucleus test, dominant lethal test in mice, cytogenetic assay in Chinese hamster bone marrow cells).</p><p>No tumorigenic or carcinogenic effects were demonstrated in long-term studies in mice and rats. <u>Reproductive and developmental toxicity</u></p><p>Studies to investigate the possible influence of ipratropium bromide on fertility, embryo-/foetotoxicity</p><p>and peri-/postnatal development have been performed in mice, rats and rabbits.</p><p>High oral doses (1000 mg/kg/day in rats and 125 mg/kg/day in rabbits) were maternotoxic for both species and embryo-/foetotoxic in rats and resulted in lower foetal weight. Malformations related to ipratropium bromide were not observed. The highest technically feasible doses for inhalation of the metered-dose aerosol (1.5 mg/kg/day in rats and 1.8 mg/kg/day in rabbits) had no adverse effects on reproduction.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride, hydrochloric acid 3.6% (for pH adjustment), purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Atrovent UDVs 500 &micro;g/2 ml and disodium cromoglicate solutions should not be administered simultaneously in the same nebuliser.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &ordm;C. Keep vials in the original carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear, colourless nebuliser solution in a colourless, transparent PE unit-dose vial. The unit-dose vials are packed in 10s in hermetically sealed white aluminium pouches.</p><p>&nbsp;</p><p><u>Pack sizes</u>:</p><p>Pack containing 50 unit-dose vials each holding 2 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution is ready to use and does not need to be diluted. It is intended only for inhalation with suitable inhalation devices and must not be taken orally or administered parenterally.</p><p>&nbsp;</p><p>The solution should ideally be administered with the patient in a sitting or standing position.</p><p>&nbsp;</p><p>Instructions for use</p><p>1.&nbsp;&nbsp; Get the inhalation device (nebuliser) ready in accordance with the instructions provided by the manufacturer and your doctor.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp; Separate one unit-dose vial from the strip (Fig. 1).</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image2.jpeg" o:spid="_x0000_i1027" type="#_x0000_t75"
 style='width:73pt;height:73pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="97" height="97" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>Fig. 1</p><p>&nbsp;</p><p>3.&nbsp;&nbsp; Open the vial by twisting off the top (Fig. 2).</p><p><!--[if gte vml 1]><v:shape
 id="image3.jpeg" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:73pt;
 height:73pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="97" height="97" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p><p>Fig. 2</p><p>&nbsp;</p><p>4.&nbsp;&nbsp; Squeeze all the contents of the vial into the nebuliser chamber (Fig. 3).</p><p><!--[if gte vml 1]><v:shape
 id="image4.jpeg" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:73pt;
 height:73pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="97" height="97" src="file:///C:/Users/abalkhai/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p><p>Fig. 3</p><p>&nbsp;</p><p>5.&nbsp;&nbsp; Assemble the nebuliser and use as directed.</p><p>&nbsp;</p><p>6.&nbsp;&nbsp; After use, dispose of any solution remaining in the nebuliser chamber and then clean the nebuliser, following the manufacturer&#39;s instructions.</p><p>&nbsp;</p><p>Patients must be instructed in the correct use of Atrovent UDVs 500 &micro;g/2 ml.</p><p>&nbsp;</p><p>Care must be taken not to allow the solution or mist to enter the eyes. The nebulised solution should be administered via a mouthpiece. If a mouthpiece is not available and a nebuliser mask is used, care must be taken to ensure that it fits properly. Patients who are predisposed to glaucoma should take particular care to ensure their eyes are protected during inhalation.</p><p>&nbsp;</p><p>As the solution contains no preservatives, the contents of the vial must be inhaled immediately after opening. Any solution left in the vial should be discarded.</p><p>&nbsp;</p><p>A fresh vial should be used for each dose. Partly-used, damaged or accidentally opened vials must be discarded.</p><p>&nbsp;</p><p>Atrovent UDVs 500 &micro;g/2 ml can be administered using a range of commercially available nebulisers. Where wall oxygen is available, the solution is best administered at a flow rate of 6 - 8 l/min.</p><p>&nbsp;</p><p>Atrovent UDVs 500 &micro;g/2 ml are suitable for concurrent inhalation with mucolytic agents such as ambroxol hydrochloride and bromhexine hydrochloride or fenoterol hydrobromide.</p><p>&nbsp;</p><p>Throw away unused medicines or waste material according to national requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7.	MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Pharma GmbH & Co. KG Binger Str. 173
55216 Ingelheim am Rhein Germany

8.	MARKETING AUTHORISATION NUMBER(S)

37146.00.00

9.	DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 09.07.1998
Date of renewal of the authorisation: 10.02.2004

10.	DATE OF REVISION OF THE TEXT

August 2020

11.	GENERAL CLASSIFICATION FOR SUPPLY

Prescription only

Please report adverse drug events to: 
•	Saudi Arabia: 
The National Pharmacovigilance Centre [NPC]: 
o	SFDA Call Center: 19999 
o	E-mail: npc.drug@sfda.gov.sa 
o	Website: https://ade.sfda.gov.sa/ 
•	Other GCC States: Please contact the relevant competent authority

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>